Welcome to eBiochemicals.
|Smiles||FC1=CC=C(F)C=C1[[email protected]](CN2C=NC=N2)(O)[[email protected]@H](C)C3=NC(C4=CC=C(C#N)C=C4)=CS3|
|Synonyms||Isavuconazole; RO 0094815; 4-(2-((2R,3R)-3-(2,5-difluorophenyl)-3-hydroxy-4-(1H-1,2,4-triazol-1-yl)butan-2-yl)thiazol-4-yl)benzonitrile|
|Isavuconazole(BAL-4815; RO-0094815) is the active component of the new azole antifungal agent BAL8557, exhibits MIC(50)s/MIC(90)s ranged from 0.002/0.004 mg/liter for C. albicans to 0.25/0.5 mg/liter for C. glabrata. IC50 value: Target: antifungal agent in vitro: Isavuconazole was more active (0.004 mg/liter) than amphotericin B (0.5 mg/liter), itraconazole (0.008 mg/liter), voriconazole (0.03 mg/liter), flucytosine (0.125 mg/liter), and fluconazole (8 mg/liter). There were only two isolates with MICs for isavuconazole that were >0.5 mg/liter: both were C. glabrata isolates, and the MICs were 2 and 4 mg/liter, respectively . Isavuconazole has MIC90 value of 0.016 microg/ml against Cryptococcus neoformans isolates from Cuba . Protocol(Only for Reference)  Antifungal susceptibility testing: Broth microdilution was performed by the reference method described by the CLSI (formerly National Committee for Clinical Laboratory Standards) in accordance with guideline M27-A2 (5), with a final inoculum concentration of 0.5 × 103 to 2.5 × 103 cells per ml and RPMI 1640 medium (Sigma, Steinheim, Germany) buffered to pH 7.0 with 0.165 M MOPS (morpholinepropanesulfonic acid) buffer (Merck, Darmstadt, Germany). Microtiter plates containing dehydrated antifungal agents were provided by Merlin Diagnostica (Bornheim-Hersel, Germany). The antifungal agents and concentration ranges tested in twofold steps were as follows: amphotericin B, 0.03 to 32 mg/liter; flucytosine, 0.03 to 64 mg/liter; fluconazole, 0.06 to 128 mg/liter; itraconazole, 0.004 to 8 mg/liter; voriconazole, 0.004 to 8 mg/liter; and isavuconazole, 0.00025 to 8 mg/liter. Plates were incubated in air at 35°C for 24 to 48 h. Plates were observed for the presence or absence of growth at 24 h and reexamined at 48 h if sufficient growth was not obtained at 24 h. The MIC was determined visually as the lowest concentration of drug showing no growth for amphotericin B and a prominent reduction of growth (≥50%) for flucytosine and the azoles compared to the drug-free growth control. C. parapsilosis ATCC 22019 and C. krusei ATCC 6258 were used as quality control strains. ......by MedChemexpress Co., Ltd.|
|Isavuconazole(BAL-4815; RO-0094815) is the active component of the new azole antifungal agent BAL8557, exhibits MIC(50)s/MIC(90)s ranged from 0.002/0.004 mg/liter for C. albicans to 0.25/0.5 mg/liter for C. glabrata. ......by Target Molecule Corp.|
|Company||Price and Availability||Country/Region|
|MedChemexpress Co., Ltd.||1mg/USD180(In stock);5mg/USD780(In stock)||USA|
|Pure Chemistry Scientific Inc.||1mg/USD286(In stock)||USA|
|Shanghai Haoyuan Chemexpress Co., Ltd.||China|
|Target Molecule Corp.||1mg/USD112();5mg/USD320();10mg/USD520();25mg/USD824();50mg/USD1260()||USA|
. Illnait-Zaragozi MT, et al. In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. Antimicrob Agents Chemother. 2008 Apr;52(4):1580-2.